Biodesix announces closing of upsized public offering and full exercise of option to purchase additional shares

Boulder, colo.--( business wire )--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the closing of its underwritten public offering of 35,075,000 shares of its common stock at a price to the public of $1.15 per share, including the exercise in full by the underwriter of its option to purchase up to an additional 4,575,000 shares of common stock in the offering. the gross proceeds to biodesix from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by biodesix, were $40.3 million.
BDSX Ratings Summary
BDSX Quant Ranking